What’s Health Canada Saying about Biosimilars?
Written by: CDHF
Updated: November 9th, 2022
A biosimilar biologic drug, or biosimilar, is a drug demonstrated to be highly similar to a biologic drug that was already authorized for sale (known as the reference biologic drug). Biosimilars are approved based on a thorough comparison to a reference drug and may enter the market after the expiry of reference drug patents and data protection. Watch this video to get more insight into what Health Canada is saying about biosimilars! Learn more about biosimilars here.
This video was made possible by an unrestricted educational grant by Pfizer Canada.
